Probably Jiong Ma is a good asset for the company, but with no experience at all in launching a new drug in the market.
I looked at board members, management and Linkedin profiles. There is really nobody with medical, marketing, market access, or sales experience launching a drug. At this stage they need to build KOL support to get the drug approved and reimbursed in the major countries. That doesn't go by itself and takes time. Anyone who has ever launched a drug knows that. Such colleagues would know how to do premarketing, build a story around a new drug, create effective messages, prepare various activities and build a network of external key opinion leaders (KOLs) supporting the drug and company. That all lacks here. Also regulators and payers sometimes speak with KOLs about new developments and if they don't hear anything positive it will be bad for the company and drug. All big companies nowadays start (very) early on with some marketing, medical and market access persons. Now there is nobody which explains the amateuristic communications, materials, the lack of activities and share price. The competitors will speak about Anavex in a negative way and there is nothing to balance that somewhat.
I agree that the data looks promising, but the share price is ridiculously low and that's mostly because they do not know how to build support for the drug. Missling uses his scientific gut feeling to guide him and nobody tells him that it doesn't work this way.
AI
Market Data 
Markets 
